1359431-16-5
1359431-16-5
Chemical Structure
M435-1279
- CAS No.: 1359431-16-5
- Formula:C18H17N3O5S2
- Molecular Weight:419.47
IUPAC Name: 4-hydroxy-2-oxo-N-(4-sulfamoylphenyl)-1,2,5,6,7,8-hexahydrobenzo[4,5]thieno[2,3-b]pyridine-3-carboxamide
InChIKey: MVQJFYRZMPKNIV-UHFFFAOYSA-N
SMILES: O=C(C1=C(O)C2=C(SC3=C2CCCC3)NC1=O)NC4=CC=C(S(=O)(N)=O)C=C4
Biological Activity: M435-1279 is a UBE2T inhibitor. M435-1279 inhibits the Wnt/β-catenin signaling pathway hyperactivation through blocking UBE2T-mediated degradation of RACK1[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
M435-1279 | 98.28% | M435-1279 is a UBE2T inhibitor. M435-1279 inhibits the Wnt/β-catenin signaling pathway hyperactivation through blocking UBE2T-mediated degradation of RACK1. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Yu Z, et al. A novel UBE2T inhibitor suppresses Wnt/β-catenin signaling hyperactivation and gastric cancer progression by blocking RACK1 ubiquitination. Oncogene. 2021 Feb;40(5):1027-1042. doi: 10.1038/s41388-020-01572-w. Epub 2020 Dec 15. Erratum in: Oncogene. 2021 Apr;40(14):2622-2623. [Content Brief]
